SLC5A2 and diabetic kidney disease: Recent clinical trials showed that even non-diabetic patients experience the benefits of SGLT2 inhibitors; preclinical studies that use non-diabetic kidney disease models, such as renal ischemia-reperfusion injury (IRI) model, proteinuric non-diabetic nephropathy model, and renal injury in prediabetic rat models, revealed the protective effect of SGLT2 inhibitors [7–12].